Trifluridine and tipiracil safe, effective for pretreated metastatic gastric cancer regardless of prior gastrectomy

Trifluridine and tipiracil significantly extended PFS and OS compared with placebo among patients with previously treated metastatic gastric or gastroesophageal junction cancer, according to results of a subgroup analysis of the randomized phase 3 TAS-102 Gastric Study.The oral nucleoside antitumor agent trifluridine and tipiracil (Lonsurf, Taiho Oncology) — also called TAS-102 — demonstrated safety and efficacy regardless of whether patients had undergone gastrectomy.“This is an important observation, as TAS-102 is an oral agent potentially influenced by drug absorption andRead More